Regulus Therapeutics Inc Share Price Nasdaq
Equities
US75915K1016
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 149M 12.4B |
---|---|---|---|---|---|
Net income 2024 * | -33M -2.75B | Net income 2025 * | -46M -3.84B | EV / Sales 2024 * | - |
Net cash position 2024 * | 94.2M 7.86B | Net cash position 2025 * | 50.8M 4.24B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.47
x | P/E ratio 2025 * |
-3.72
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 04/16/04 |
Preston Klassen
PSD | President | 55 | 22/23/22 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 30/19/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 01/17/01 |
David Baltimore
BRD | Director/Board Member | 86 | 01/09/01 |
Director/Board Member | 76 | 01/13/01 |
1st Jan change | Capi. | |
---|---|---|
+2.93% | 108B | |
-2.68% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |